Literature DB >> 9857952

Activity of tachykinin NK1 and bradykinin B2 receptor antagonists, and an opioid ligand at different stimulation parameters in neurogenic inflammation in the rat.

P K Towler1, S D Brain.   

Abstract

Stimulation of the saphenous nerve in the anaesthetised rat results in cutaneous neurogenic oedema formation. We have examined the effect of a tachykinin NK1 and a bradykinin B2 antagonist, and a mu-opioid agonist on plasma extravasation observed in response to two differing nerve stimulating parameters (10 V, 1 ms, 2 Hz and 25 V, 2 ms, 10 Hz). The NK1 antagonist SR140333 abolished oedema, supporting the theory that an NK1 agonist is a primary mediator of neurogenic oedema. The B2 antagonist HOE 140 had no effect, indicating a lack of involvement of B2 receptors in this response. The pre-junctionally acting mu-opioid agonist DAMGO significantly inhibited oedema formation at the 10 V, 1 ms, 2 Hz (P < 0.001), but not the 25 V, 2 ms, 10 Hz stimulation parameters. Thus a post-junctionally acting NK1 antagonist inhibited neurogenic oedema formation induced by both stimulation parameters, whilst a pre-junctionally acting mu-opioid agonist acted only at 10 V, 1 ms, 2 Hz parameters. These findings could be of interest with respect to therapeutic approaches of pathophysiological conditions which involve a neurogenic component.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9857952     DOI: 10.1016/s0304-3940(98)00770-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Effects of nociceptin and nocistatin on antidromic vasodilatation in hairless skin of the rat hindlimb in vivo.

Authors:  H Häbler; L Timmermann; J Stegmann; W Jänig
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Distribution of general (PGP 9.5) and sensory (substance P/CGRP) innervations in the human patellar tendon.

Authors:  Patrik Danielson; Håkan Alfredson; Sture Forsgren
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2005-06-28       Impact factor: 4.342

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.